午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Linagliptin: in type 2 diabetes mellitus.

Published:26 March 2011 DOI: 10.2165/11207400-000000000-00000 PMID: 21443284
Lesley J Scott

Abstract

Linagliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, has a favourable pharmacokinetic profile in terms of its predominantly non-renal elimination. It shows highly selective, potent, dose-dependent inhibition of DPP-4, with ≥ 80% inhibition of DPP-4 throughout the 24-hour dosing interval. In two double-blind, multicentre trials (n?>350 evaluable patients/trial) in adult patients with inadequately controlled type 2 diabetes mellitus, oral linagliptin monotherapy (5 or 10?mg once daily) was significantly more effective than placebo in improving glycaemic control and several parameters of pancreatic function, with placebo-corrected adjusted mean changes in glycosylated haemoglobin (HbA(1c)) levels of -0.69% to -0.88% after 12 or 24 weeks. Linagliptin 5 or 10?mg once daily was also significantly more efficacious than voglibose 0.2?mg three times daily in terms of improving glycaemic control in a 26-week, double-blind, multicentre trial (n?>450 evaluable patients). In several similarly designed trials (n?>250 evaluable patients/trial) of 12-24 weeks' duration in adult patients with inadequately controlled type 2 diabetes, oral linagliptin (5?mg once daily) as add-on therapy to metformin, a sulfonylurea drug or metformin plus a sulfonylurea drug, or in combination with pioglitazone, improved glycaemic control significantly more than placebo plus the respective oral antihyperglycaemic therapy, with improvements in adjusted mean HbA(1c) levels considered clinically relevant. Linagliptin, as monotherapy or in combination with other oral antihyperglycaemic drugs, was generally well tolerated in clinical trials, having neutral or minimal effects on bodyweight and generally being associated with a very low incidence of hypoglycaemia.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Linagliptin 668270-12-0 C25H28N8O2 641 suppliers $5.00-$5450.00
Voglibose 83480-29-9 C10H21NO7 528 suppliers $8.00-$1732.50
Metformin 657-24-9 C4H11N5 179 suppliers $100.00-$681.08
Pioglitazone 105355-27-9 C19H20N2O3S 39 suppliers Inquiry

Similar articles

IF:13

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Drugs Greg L Plosker,etc Published: 3 December 2012
IF:4.6

Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis.

ACS Applied Bio Materials Shuyan Gu,?Jihao Shi,etc Published: 11 May 2015
IF:4.5

Grifola frondosa Polysaccharide Ameliorates Inflammation by Regulating Macrophage Polarization of Liver in Type 2 Diabetes Mellitus Rats

Molecular Nutrition & Food Research Pei Zou, Xueyan Li,etc Published: 26 November 2024